ARTV Artiva Biotherapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1817241 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-23.9%
TTM EPS YoY-129.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-43.6%
ROA-39.9%
ROIC (approx.)-45.8%
Asset turnover—
Leverage & solvency
Liabilities / assets6.5%
Debt / equity0.00x
Current ratio19.88x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.86x
Accruals ratio-5.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | $0 |
| R&D expense | $25.99M | $21.93M | $19.31M | $16.99M | $17.63M | $17.86M | $17.05M | $13.32M |
| SG&A expense | $5.96M | $4.96M | $5.12M | $4.94M | $5.26M | $4.95M | $5.12M | $4.95M |
| Operating income | -$31.95M | -$26.89M | -$24.43M | -$21.93M | -$22.90M | -$22.81M | -$22.17M | -$18.27M |
| Net income | -$28.82M | -$25.00M | -$23.52M | -$20.77M | -$21.53M | -$21.25M | -$20.31M | -$16.09M |
| EBITDA | -$31.25M | -$26.19M | -$23.76M | -$21.27M | -$22.30M | -$22.21M | -$21.54M | -$17.65M |
| EPS (basic) | -0.56 | -0.63 | -0.95 | — | -0.88 | -0.87 | -0.83 | — |
| EPS (diluted) | -0.56 | -0.63 | -0.95 | — | -0.88 | -0.87 | -0.83 | — |
| Weighted avg. shares (diluted) | 51.20M | 39.41M | 24.68M | — | 24.48M | 24.38M | 24.34M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $61.23M | $301.45M | $20.95M | $26.70M | $25.51M | $28.47M | $30.40M | $40.49M |
| Short-term investments | $257.87M | $47.94M | $65.83M | $81.31M | $97.46M | $113.90M | $135.56M | $145.19M |
| Receivables | — | — | — | — | — | — | — | $0 |
| Current assets | $326.25M | $352.28M | $88.74M | $112.67M | $129.52M | $149.07M | $170.00M | $188.63M |
| PP&E, net | $6.17M | $5.67M | $6.22M | $6.62M | $6.98M | $6.89M | $7.06M | $6.37M |
| Total assets | $342.98M | $368.63M | $105.95M | $130.94M | $148.86M | $169.39M | $191.26M | $209.58M |
| Current liabilities | $16.41M | $14.58M | $10.88M | $13.09M | $11.12M | $10.77M | $12.20M | $12.25M |
| Total liabilities | $22.26M | $21.13M | $18.11M | $20.97M | $19.64M | $20.35M | $22.48M | $22.94M |
| Shareholders' equity | $320.72M | $347.50M | $87.85M | $109.97M | $129.22M | $149.04M | $168.78M | $186.64M |
| Cash flow statement | ||||||||
| Operating cash flow | -$28.45M | -$20.36M | -$20.95M | -$14.73M | -$19.20M | -$22.98M | -$19.84M | -$14.65M |
| Capital expenditure | $1.04M | $415,000 | $242,000 | $421,000 | $600,000 | $1.05M | $511,000 | $64,000 |
| Free cash flow | -$29.49M | -$20.77M | -$21.19M | -$15.15M | -$19.80M | -$24.04M | -$20.35M | -$14.71M |
| Investing cash flow | -$211.70M | $17.59M | $15.32M | $16.04M | $16.28M | $21.12M | $9.97M | -$966,000 |
| Financing cash flow | -$26,000 | $283.27M | -$112,000 | -$121,000 | -$37,000 | -$72,000 | $239,000 | -$30,000 |
| Depreciation & amortization | $700,000 | $700,000 | $666,000 | $666,000 | $600,000 | $600,000 | $628,000 | $614,000 |
| Stock-based compensation | $2.80M | $2.80M | $1.59M | $1.59M | $1.63M | $1.63M | $2.05M | $2.18M |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.